Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a ...
Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...
In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...
Having endured an impoverished childhood and bare-bones sickle cell care, Edward ‘Donnell’ Ivy, MD, devotes his career to ...
Asianet Newsable on MSN
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug
Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the ...
PRNewswire/ - Medunik USA, a specialty pharmaceutical company, and part of Duchesnay Pharmaceutical Group (DPG), is dedicated to providing patients with rare diseases access to orphan drugs. Medunik ...
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect ...
A community demands accountability after one Chicago mother and her young children were viciously jumped by middle schoolers— ...
The Punch on MSN
Living a life of purpose with sickle cell disease
Discover how living with sickle cell disease can become a journey of purpose. Learn to find meaning, resilience, and hope ...
Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...
The Ghana National Association of Certificated Counsellors (GNACC) has officially signed a Memorandum of Understanding (MOU) with the Focus on Sickle Cell Foundation (FoSCel) to collaborate on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback